RYAN SHAY

Issues pertaining to rural graduate mediate education program in Lugar counties and potential legislation; Policies to expand access to rural physician training programs; H.R. 4758 and S. 2372, the Accelerating Kids' Access to Care Act; Additional policies pertaining to graduate medical education.

SUSTAIN 340B Act discussion draft; H.R. 1310, the SHARE Act and issues pertaining to healthcare worker background checks; Concerns regarding the Delta Regional Authority Delta Doctor's Program; Policies to expand access to care in rual communities, policies to expand access to behavioral health services, policies to support continued access to care via telehealth.

Issues pertaining to FDA review of application for rare disease therapies; Issues pertaining to interagency coordination and management of rare disease activities; Legislation to reauthorize the Pediatric Priority Review Voucher; S. 4426 Promising Pathways Act

FY 25 appropriations legislation and provisions pertaining to coordination of rare disease activities within the FDA and HHS and funding for rare disease policies and programs.

Pharmacy Benefit Manager (PBM) reform legislation across multiple bills including S. 1339, S. 127, H.R. 3561, H.R. 4507, and H.R. 4508.

Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

House and Senate National Defense Authorization Acts; the National Defense Authorization Act

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

House and Senate National Defense Authorization Acts; the National Defense Authorization Act

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

FY 24 and FY 25 programmatic and report language pertaining to rare disease medical research, therapy development and public health activities.

Issues pertaining to FDA review of application for rare disease therapies; Issues pertaining to interagency coordination and management of rare disease activities; Legislation to reauthorize the Pediatric Priority Review Voucher.

Accelerating Kids' Access to Care Act (H.R. 4758, S. 2372) and issues pertaining to out-of-state care; Impact of Inflation Reduction Act on rare disease therapies.

FY 24 appropriations language pertaining to NIH support for pediatric research and FY 25.

S. 2345 and H.R. 4714, the Pediatricians Accelerate Childhood Therapies Act; Issues pertaining to recruitment and enrollment of children within the All of Us program; NIH reform modernization; Inclusion of child health activities within ARPA-H portfolio.

Issues pertaining to rural graduate mediate education program in Lugar counties and potential legislation; Policies to expand access to rural physician training programs.

SUSTAIN 340B Act discussion draft; H.R. 1310, the SHARE Act and issues pertaining to healthcare worker background checks; Concerns regarding the Delta Regional Authority Delta Doctor's Program; Policies to expand access to care in rual communities, policies to expand access to behavioral health services, policies to support continued access to care via telehealth.

Pharmacy Benefit Manager (PBM) reform legislation across multiple bills including S. 1339, S. 127, H.R. 3561, H.R. 4507, and H.R. 4508.

Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.

FY 2024 report language.

Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.

S. 2226 / H.R. 2670, the National Defense Authorization Act

Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.

S. 2345 and H.R. 4714, the Pediatricians Accelerate Childhood Therapies Act; Issues pertaining to recruitment and enrollment of children within the All of Us program; NIH reform modernization.

FY 24 appropriations language pertaining to NIH support for pediatric research.

Pharmacy Benefit Manager (PBM) reform legislation across multiple bills including S. 1339, S. 127, H.R. 3561, H.R. 4507, and H.R. 4508.

Issues pertaining to rural graduate mediate education program in Lugar counties and potential legislation

Issues pertaining to the healthcare workforce including S. 2243, the Palliative Care and Hospice Education and Training Act and rural health workforce concerns; concerns with Delta Regional Authority Delta Doctors Program; Ways & Means Committee rural health RFI; drug shortages; policies to advance the use of telehealth services including the Behavioral Health Information Technology Coordination Act; policies to support delivery and expansion of behavioral health care services.

Implementation of drug negotiation policy and impact on rare disease populations.

FDA policies pertaining to development of rare disease therapies; rare disease education and awareness including activities via the Congressional Rare Disease Caucus; newborn screening program policy issues.

FY 24 appropriations requests pertaining to rare disease issues.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Issues around food as medicine interventions in the Medicare program.

Issues around food as medicine interventions in the Medicare program.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Telemedicine legislation including CONNECT for Health Act; Telemental Health Care Access Act.

Telemedicine legislation including CONNECT for Health Act; Telemental Health Care Access Act; TREATS Act; Ryan Haight Act/DEA rulemaking on telemedicine; H.R. 1843, S. 1001 - Telehealth Expansion Act; H.R. 824 Telehealth Benefit Expansion for Workers Act.

Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board; issues related to S. 2860, the SAFER Banking Act.

Continuation of first-dollar coverage for telehealth H.R. 1843, S. 1001 - Telehealth Expansion Act; Telehealth ERISA exemption H.R. 824 Telehealth Benefit Expansion for Workers Act; CONNECT for Health Act; Telemental Health Care Access Act; health care data transparency; telehealth in Medicare Advantage; streamlining Medicaid provider enrollment.

S. 2226 / H.R. 2670, the National Defense Authorization Act

Issues pertaining to rural graduate mediate education program in Lugar counties and potential legislation

Issues pertaining to the healthcare workforce including S. 2243, the Palliative Care and Hospice Education and Training Act and rural health workforce concerns; concerns with Delta Regional Authority Delta Doctors Program; Ways & Means Committee rural health RFI; drug shortages.

Pharmacy Benefit Manager (PBM) reform legislation across multiple bills including S. 1339, S. 127, H.R. 3561, H.R. 4507, and H.R. 4508.

FDA policies pertaining to development of rare disease therapies; rare disease education and awareness including activities via the Congressional Rare Disease Caucus.

Implementation of drug negotiation policy and impact on rare disease populations.

FY 24 appropriations requests pertaining to rare disease issues.

FY 24 appropriations language pertaining to NIH support for pediatric research.

S. 2345 and H.R. 4714, the Pediatricians Accelerate Childhood Therapies Act. Issues pertaining to recruitment and enrollment of children within the All of Us program.

FY 2024 report language.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Issues around food as medicine interventions in the Medicare program.

Issues related to advanced and additive manufacturing; appropriations; National Defense Authorization Act.

FY 24 appropriations requests pertaining to rare disease issues

Implementation of drug negotiation policy and impact on rare disease populations.

Issues pertaining to development of therapies for rare diseases including oversight of FDAs structure for rare disease applications; engagement on FDA guidance document; S. 1214, the RARE Act; activities of the Congressional Rare Disease Caucus.

FY 24 appropriations language pertaining to NIH support for pediatric research.

Research issues pertaining to children; recruitment of children into All of Us Research Program; pediatric research considerations for ARPA-H. Issues regarding NIH support for pediatric research; support for early-career researchers; reintroduction of the Pediatricians Accelerate Childhood Therapies Act.

Pharmacy benefit manager (PBM) reform legislation including S. 1339, and S. 127 and related activities.

Issues pertaining to the healthcare workforce including response to Senate HELP RFI; issues pertaining to the 340B program including response to Senate RFI; the Fiscal Responsibility Act and implications for healthcare providers including implications on PRF funding; legislative pertaining to transparency in healthcare pricing.

Issues pertaining to rural graduate mediate education program in Lugar counties and potential legislation

FY 24 community project funding.

Telemedicine legislation including CONNECT for Health Act; Telemental Health Care Access Act; TREATS Act; Ryan Haight Act/DEA rulemaking on telemedicine; H.R. 1843, S. 1001 - Telehealth Expansion Act; H.R. 824 Telehealth Benefit Expansion for Workers Act.

Telemedicine legislation including CONNECT for Health Act; Telemental Health Care Access Act.

Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses; Establishment of the National Association of Registered Agents & Brokers board.

Issues around food as medicine interventions in the Medicare program.

Issues around food as medicine interventions in the Medicare program.

Issues around food as medicine interventions in the Medicare program.

Issues related to advanced and additive manufacturing; appropriations; National Defense Authorization Act.

Issues related to compounding medications, including safety and supply chain issues.

Issues related to compounding medications, including safety and supply chain issues.

Issues related to compounding medications, including safety and supply chain issues.

Issues pertaining to pharmacy benefit manager (PBM) services including legislation and oversight activity. PBM issues including S. 127, the PBM Transparency Act of 2023 and other PBM-related legislation.

Issues related to extension of the National Flood Insurance Program; enactment of a safe harbor for insurers of state-legal cannabis businesses.

FY 2024 report language.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Research issues pertaining to children; recruitment of children into All of Us Research Program; pediatric research considerations for ARPA-H. Issues regarding NIH support for pediatric research; support for early-career researchers; reintroduction of the Pediatricians Accelerate Childhood Therapies Act.

FY 24 appropriations language pertaining to NIH support for pediatric research.

Issues pertaining to rare disease interests including how FDA structural matters.

FY 24 appropriations requests pertaining to rare disease issues

Implementation of drug negotiation policy and impact on rare disease populations.

FY 24 community project funding.

Issues pertaining to rural graduate mediate education program in Lugar counties and potential legislation

General healthcare issues, healthcare workforce and staffing concerns.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

Advocacy on all government relations matters, including Congressionally-Directed Spending requests, the National Center for Advanced Manufacturing, and other education policy matters.

H.R. 5370 Medically Tailored Home-Delivered Meals Demonstration Pilot Act of 2021 - issues around food is medicine.

H.R. 5370 Medically Tailored Home-Delivered Meals Demonstration Pilot Act of 2021 - issues around food is medicine.

H.R. 5370 Medically Tailored Home-Delivered Meals Demonstration Pilot Act of 2021 - issues around food is medicine.

Issues related to compounding medications, including safety and supply chain issues.

Issues related to compounding medications, including safety and supply chain issues.

Issues related to compounding medications, including safety and supply chain issues.

Report language and accelerated approval provisions in H.R. 2471 - Consolidated Appropriations Act of 2022.

Community Project funding within FY 23 Consolidated Appropriations Act.

Mental and behavioral health policy; extension of telehealth flexibilities, update of national patient safety strategy, policies pertaining to insulin pricing, pharmacy benefit manager (PBM) legislative proposals.

S. 2209 and H.R. 4128, the Pediatricians Accelerate Childhood Therapies (PACT) Act and issues pertaining to early-career pediatric researchers, inclusion of children within the All of Us (Precision Medicine) program; ARPA-H and inclusion of pediatrics within the program; VALID Act and potential impact on pediatric research activities.

FY 23 appropriations legislation and policies pertaining to development of early-career pediatric researchers.

FY 23 appropriations legislation and policies pertaining to rare disease programs.

H.R. 1730, S. 670 the Speeding Therapy Access Today (STAT) Act and related rare disease policy issues and inclusion of policies in year-end omnibus.

Issues related to Additive Manufacturing.

Advocating for food-as-medicine priorities in Congressional legislation and Medicare pilot programs.

Advocating for food-as-medicine priorities in Congressional legislation and Medicare pilot programs.

Advocating for food-as-medicine priorities in Congressional legislation and Medicare pilot programs.

Issues related to compounding medications, including safety and supply chain issues.

Issues related to compounding medications, including safety and supply chain issues.

Issues related to compounding medications, including safety and supply chain issues.

Mental and behavioral health legislation; S. 4293, the Pharmacy Benefit Transparency Act and other legislation items and proposals pertaining to pharmacy benefit managers; public health emergency and other items pertaining to COVID-19.

FY 23 appropriations legislation including community project requests.

Issues related to Additive Manufacturing.

Authorizing bills for the Advanced Research Projects Agency - Health (ARPA-H); H.R. 5585 - Advanced Research Project Agency-Health Act. Prescription Drug User Fee Act reauthorization bills: Food and Drug Amendments of 2022 (H.R. 7667) FDASLA Act of 2022 (S. 4348).

FY 23 appropriations legislation and policies pertaining to development of early-career pediatric researchers.

S. 2209 and H.R. 4128, the Pediatricians Accelerate Childhood Therapies (PACT) Act and issues pertaining to early-career pediatric researchers, inclusion of children within the All of Us (Precision Medicine) program.

FY 23 appropriations legislation and policies pertaining to rare disease programs.

Potential changes to the Orphan Drug Tax Credit (ODTC) and other issues within budget reconciliation.

H.R. 1730, S. 670 the Speeding Therapy Access Today (STAT) Act and related rare disease policy issues, FDA user fee reauthorization legislation (H.R. 7667 and S. 4348), Accelerated Approval pathway, VALID Act.

Tax and benefits implications of Social Security and other federal programs, laws, and regulations for elders and/or individuals with disabilities or their families. Special needs trusts. Veterans' benefits. Pensions & retirement plans. Age discrimination and public accommodation under ADA and other laws, decisions, rules, policies. Workplace accommodations and antidiscrimination for elders and/or those with disabilities or their families. FMLA. Elder and disabled person abuse/protections.

Tax and benefits implications of Social Security and other federal programs, laws, and regulations for elders and/or individuals with disabilities or their families. Special needs trusts. Veterans' benefits. Pensions & retirement plans. Age discrimination and public accommodation under ADA and other laws, decisions, rules, policies. Workplace accommodations and antidiscrimination for elders and/or those with disabilities or their families. FMLA. Elder and disabled person abuse/protections.

Additive manufacturing policies.

FY 23 appropriations legislation and policies pertaining to psoriatic disease public health activities.

Authorizing bills for the Advanced Research Projects Agency - Health (ARPA-H); H.R. 5585 - Advanced Research Project Agency-Health Act. Prescription Drug User Fee Act reauthorization bills: Food and Drug Amendments of 2022 (H.R. 7667) FDASLA Act of 2022 (S. 4348).

Issues related to compounding medications, including safety and supply chain issues.

Issues related to compounding medications, including safety and supply chain issues.

Issues related to compounding medications, including safety and supply chain issues.

FY 23 appropriations legislation and policies pertaining to development of early-career pediatric researchers.

Support for early-career pediatric researchers including the Pediatricians Accelerate Childhood Therapies (PACT) Act (S. 1357 and H.R. 3773); prescription drug user fee legislation specifically the VALID Act (S. 2209 and H.R. 4128) and its impact on diagnostic tests for pediatrics.

Issues pertaining to COVID-19 response including access to therapies; mental and behavioral health; S. 4293, the Pharmacy Benefit Transparency Act and other legislation items and proposals pertaining to pharmacy benefit managers; public health emergency and other items pertaining to COVID-19.

FY 23 appropriations legislation including community project requests.

FY 23 appropriations legislation and policies pertaining to rare disease programs.

H.R. 1730, S. 670 the Speeding Therapy Access Today (STAT) Act and related rare disease policy issues, FDA user fee reauthorization legislation (H.R. 7667 and S. 4348), Accelerated Approval pathway, VALID Act.

WHOIS; Communications Decency Act; Section 230 reform.

S. 936 - The Integrity, Notification, and Fairness in Online Retail Marketplaces for Consumers (INFORM Consumers) Act of 2021; H.R. 3429 - the Stopping Harmful Offers on Platforms by Screening Against Fakes in E-Commerce (SHOP SAFE) Act of 2021.

Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability regarding COVID-19 frauds; STOP Act implementation; S.3399, H.R. 6352 - Domain Reform for Unlawful Drug Sellers Act (DRUGS Act).

Support for funding to address research costs incurred as a result of the COVID-19 pandemic; Policies supporting pediatric research including training of early-career researchers and the Trans-NIH Pediatric Research Consortium (N-PeRC); FY 23 appropriations including policies pertaining to development of early-stage pediatric researchers.

Support for early-career pediatric researchers including the Pediatricians Accelerate Childhood Therapies (PACT) Act (S. 1357 and H.R. 3773); 21st Century Cures 2.0.

FY 22 appropriations and omnibus; FY 23 appropriations issues of relevance to the rare disease community including newborn screening, medical research, therapy development and diagnosis coding; FY 2022 budget reconciliation and issues of interest to rare disease community.

H.R. 1730, S. 670 - the Speeding Therapy Access Today (STAT) Act; Related rare disease policies; Reauthorization of the Prescription Drug User Fee Act; including Accelerated Approval pathway.

FY 2023 funding for Chronic Disease Education and Awareness and programs focused on psoriasis and psoriatic arthritis.

Educate Congress on the compounding pharmacy industry and its role in providing patient access to medicines; support policies to advance industry compliance with FDA and state compound pharmacy requirements.

COVID response measures related to healthcare providers, Medicare Graduate Medical Education (GME), health equity and related policies, mental and behavioral health.

COVID response measures related to healthcare providers, Medicare Graduate Medical Education (GME), health equity and related policies, mental and behavioral health.